Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Susceptibility

In Vitro Activities of Omadacycline against Rapidly Growing Mycobacteria

Carolyn Shoen, David Benaroch, Mary Sklaney, Michael Cynamon
Carolyn Shoen
aCentral New York Research Corporation, Syracuse, New York, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Benaroch
aCentral New York Research Corporation, Syracuse, New York, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mary Sklaney
aCentral New York Research Corporation, Syracuse, New York, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Cynamon
aCentral New York Research Corporation, Syracuse, New York, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/AAC.02522-18
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

The in vitro activity of omadacycline, a new tetracycline derivative, was evaluated against isolates of Mycobacterium abscessus, Mycobacterium chelonae, and Mycobacterium fortuitum using a broth microtiter dilution assay. Omadacycline had MIC90 values of 2 μg/ml, 0.25 μg/ml, and 0.5 μg/ml, respectively. The in vitro activity of omadacycline against rapidly growing mycobacteria indicates that it may have the potential to improve therapy for infections caused by these organisms.

INTRODUCTION

Infections caused by Mycobacterium abscessus, Mycobacterium chelonae, and Mycobacterium fortuitum occur more frequently in immunocompromised individuals than in healthy humans. When they do occur, they are difficult to treat and do not respond well to antimicrobials used for other mycobacterial infections (1).

M. abscessus is the third most common nontuberculous mycobacterial (NTM) respiratory pathogen recovered from lungs in the United States (1). Clinical infections can range from asymptomatic to severe bronchiectasis and/or cavitary lung disease. M. abscessus is inherently multidrug resistant. Drug regimens are selected on the basis of results from in vitro susceptibility studies. The optimal therapeutic regimen and treatment duration are not well established. M. chelonae causes a range of diseases, including cellulitis and eye infections. M. chelonae is often found in water heaters, pedicure beds, and tattoo parlors (2). It is often treated with azithromycin or clarithromycin. M. fortuitum is usually associated with soft tissue infections and hospital-acquired postoperative infections in immunocompromised hosts.

Omadacycline (OMC) is a new intravenous and oral tetracycline derivative with potent in vitro and in vivo activities against many drug-resistant pathogens, including common Gram-positive aerobes, many Gram-negative aerobes, anaerobes, and atypical bacterial pathogens (3, 4). The activity of OMC in the presence of tetracycline-specific efflux pumps and ribosomal protection is conferred by substitutions at C-7 and C-9, respectively (Fig. 1).

FIG 1
  • Open in new tab
  • Download powerpoint
FIG 1

Chemical structures of omadacycline, tigecycline, and doxycycline.

The purpose of the present study was to evaluate the in vitro activities of OMC, doxycycline (DOX), and tigecycline (TGC) against clinical isolates of M. abscessus complex, M. chelonae, and M. fortuitum. Amikacin (AMK) served as a control drug.

OMC, TGC, DOX, and AMK were obtained from Paratek Pharmaceuticals (Boston, MA), Carbosynth (San Diego, CA), Sigma Chemical Co. (St. Louis, MO), and Bristol Meyers Squibb (Princeton, NJ), respectively. OMC, TGC, and DOX were dissolved in double-distilled water at a final concentration of 2 mg/ml and sterile filtered through a 0.22-μm filter (Corning, Inc., Corning, NY). AMK was dissolved in dimethyl sufoxide at a final concentration of 5 mg/ml. The drugs were frozen at −20°C until used.

M. abscessus complex and M. fortuitum isolates were kindly provided by Barbara Body (LabCorp, Burlington, NC) and Barbara Brown-Elliot (University of Texas Health Science Center, Tyler, TX). The isolates were grown in cation-adjusted Mueller-Hinton broth (CAMHB; Becton-Dickinson, Sparks, MD) on a rotary shaker at 37°C for 2 or 5 days, respectively. The cultures were diltuted to 10 Klett units (equivalent to 5 × 107 CFU/ml) (photoelectric colorimeter; Manostat Corp., New York, NY) and frozen at −70°C until used. M. chelonae isolates were provided by Barbara Brown-Elliot. The isolates were grown on cation-adjusted Mueller-Hinton agar at 32°C for 3 to 5 days prior to testing.

Polystyrene 96-well round-bottom microtiter plates (Corning, Inc., Corning, NY) were prepared by adding 50 μl of CAMHB to each well. The antimicrobial compounds were thawed and diluted in CAMHB. Fifty microliters of each solution was added to the first well and serially diluted, leaving the last well with broth only (positive-control well). M. abscessus and M. fortuitum isolates were thawed and diluted in CAMHB to a final concentration of approximately 1 × 105 CFU/ml (inoculum range for M. abscessus, 1.2 × 104 to 2.6 × 105 CFU/ml, and for M. fortuitum, 1.3 × 104 to 2.4 × 106 CFU/ml). M. chelonae was prepared by placing several colonies of each isolate in CAMHB, sonicating for 5 to 10 min, and diluting to approximately 1 × 105 CFU/ml (inoculum range, 2.6 × 104 to 3.2 × 106 CFU/ml). To each well, 50 μl of the appropriate mycobacterial cell suspension was added. Plates were sealed and incubated at 37°C in ambient air for 2 days (M. fortuitum) or 5 days (M. abscessus) or incubated at 32°C for 4 days (M. chelonae) prior to reading. Each isolate was tested in duplicate, with one isolate of each species serving as a control strain. The MIC was defined as the lowest concentration of antimicrobial agent yielding no visible turbidity. The MIC50 and MIC90 values are defined as the concentrations at which 50% and 90% of the isolates were inhibited, respectively.

The MICs of OMC, TGC, DOX, and AMK against 24 isolates of the M. abscessus complex are presented in Table 1. The MIC50 and MIC90 of OMC, DOX, and AMK against M. abscessus were 1 μg/ml and 2 μg/ml, >64 μg/ml and >64 μg/ml, and 2 μg/ml and 8 μg/ml, respectively. TGC was tested against a subset of these organisms (n = 14) and was found to have activity similar to that of OMC.

View this table:
  • View inline
  • View popup
TABLE 1

MICs of omadacycline, doxycycline, and tigecycline against 24 isolates of the Mycobacterium abscessus complex

The MICs of OMC, TGC, DOX, and AMK against 22 isolates of M. chelonae are presented in Table 2. The MIC50 and MIC90 of OMC, TGC, DOX, and AMK against M. chelonae were 0.125 μg/ml and 0.25 μg/ml, 0.06 μg/ml and 0.25 μg/ml, 32 μg/ml and 64 μg/ml, and 4 μg/ml and 8 μg/ml, respectively.

View this table:
  • View inline
  • View popup
TABLE 2

MICs of OMC, DOX, and TGC against 22 isolates of Mycobacterium chelonae

The MICs of OMC, TGC, DOX, and AMK against 20 isolates of M. fortuitum are presented in Table 3. The MIC50 and MIC90 of OMC, TGC, DOX, and AMK against M. fortuitum were 0.125 μg/ml and 0.5 μg/ml, 0.25 μg/ml and 0.5 μg/ml, 8 μg/ml and 64 μg/ml, and 0.5 μg/ml and 4 μg/ml, respectively.

View this table:
  • View inline
  • View popup
TABLE 3

MICs of OMC, DOX, and TGC against 20 isolates of Mycobacterium fortuitum

OMC and TGC had similar in vitro activities against M. abscessus, M. chelonae, and M. fortuitum. The MICs of OMC were lower than those of DOX and were less than or equal to those of AMK for all isolates tested. In vitro evaluation of OMC against a larger group of isolates would be useful, as would in vivo studies in a murine test system. The in vitro activity of OMC suggests that further development as a potential therapy for infections caused by rapidly growing mycobacteria is warranted.

ACKNOWLEDGMENT

This work was supported in part by Paratek Pharmaceuticals, Inc.

FOOTNOTES

    • Received 10 December 2018.
    • Returned for modification 3 January 2019.
    • Accepted 6 February 2019.
    • Accepted manuscript posted online 11 March 2019.
  • Copyright © 2019 American Society for Microbiology.

All Rights Reserved.

REFERENCES

  1. 1.↵
    1. Griffith DE,
    2. Aksamit T,
    3. Brown-Elliott BA,
    4. Catanzaro A,
    5. Daley C,
    6. Gordin F,
    7. Holland SM,
    8. Horsburgh R,
    9. Huitt G,
    10. Iademarco MF,
    11. Iseman M,
    12. Olivier K,
    13. Ruoss S,
    14. von Reyn CF,
    15. Wallace RJ, Jr,
    16. Winthrop K
    . 2007. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 175:367–416. doi:10.1164/rccm.200604-571ST.
    OpenUrlCrossRefPubMedWeb of Science
  2. 2.↵
    1. Falkinham J
    . 2011. Nontuberculous mycobacteria from household plumbing of patients with nontuberculous mycobacteria disease. Emerg Infect Dis 17:419–424. doi:10.3201/eid1703.101510.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Macone AB,
    2. Caruso BK,
    3. Leahy Rg,
    4. Donatelli J,
    5. Weir S,
    6. Draper MP,
    7. Tanaka SK,
    8. Levy SB
    . 2014. In vitro and in vivo antibacterial activities of omadacycline, a novel aminomethylcycline. Antimicrob Agents Chemother 58:1127–1135. doi:10.1128/AAC.01242-13.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Tanaka SK,
    2. Steenbergen J,
    3. Villano S
    . 2016. Discovery, pharmacology, and clinical profile of omadacycline, a novel aminomethylcycline antibiotic. Bioorg Med Chem 24:6409–6419. doi:10.1016/j.bmc.2016.07.029.
    OpenUrlCrossRef
View Abstract
PreviousNext
Back to top
Download PDF
Citation Tools
In Vitro Activities of Omadacycline against Rapidly Growing Mycobacteria
Carolyn Shoen, David Benaroch, Mary Sklaney, Michael Cynamon
Antimicrobial Agents and Chemotherapy Apr 2019, 63 (5) e02522-18; DOI: 10.1128/AAC.02522-18

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Antimicrobial Agents and Chemotherapy article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
In Vitro Activities of Omadacycline against Rapidly Growing Mycobacteria
(Your Name) has forwarded a page to you from Antimicrobial Agents and Chemotherapy
(Your Name) thought you would be interested in this article in Antimicrobial Agents and Chemotherapy.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
In Vitro Activities of Omadacycline against Rapidly Growing Mycobacteria
Carolyn Shoen, David Benaroch, Mary Sklaney, Michael Cynamon
Antimicrobial Agents and Chemotherapy Apr 2019, 63 (5) e02522-18; DOI: 10.1128/AAC.02522-18
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • INTRODUCTION
    • ACKNOWLEDGMENT
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

nontuberculous mycobacteria
antimicrobials
in vitro

Related Articles

Cited By...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596